Sotac Pharmaceuticals Limited (NSE: SOTAC)

Market Cap	1.22B
Revenue (ttm)	1.05B
Net Income (ttm)	44.60M
Shares Out	11.05M
EPS (ttm)	4.04
PE Ratio	27.43
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,600
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	87.10 - 202.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 4, 2025

About Sotac Pharmaceuticals

Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, anti-allergic, dermatological products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin. The company also offers beta and ...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 68
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SOTAC

Financial Performance

In 2023, Sotac Pharmaceuticals's revenue was 1.04 billion, an increase of 34.13% compared to the previous year's 774.83 million. Earnings were 42.81 million, an increase of 48.69%.